{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:17:59Z","timestamp":1784827079323,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-35684-2","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:24:17Z","timestamp":1769581457000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigation of Acoramidis-based ionic liquids as potential stabilizers of transthyretin using DFT calculations, molecular docking, and ADMET studies"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9583-6983","authenticated-orcid":false,"given":"Fatemeh","family":"Mostaghni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nosrat Madadi","family":"Mahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"35684_CR1","doi-asserted-by":"publisher","first-page":"23313","DOI":"10.1038\/s41598-024-74289-5","volume":"14","author":"P Simon","year":"2024","unstructured":"Simon, P., Behrens, H. M., Kristen, A. & R\u00f6cken, C. Myocardial inflammatory cells in cardiac amyloidosis. Sci. Rep. 14, 23313. https:\/\/doi.org\/10.1038\/s41598-024-74289-5 (2024).","journal-title":"Sci. Rep."},{"key":"35684_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13023-025-03547-0","volume":"20","author":"D Delgado","year":"2025","unstructured":"Delgado, D. et al. Epidemiology of transthyretin (ATTR) amyloidosis: A systematic literature review. Orphanet J. Rar. Dis. 20, 29. https:\/\/doi.org\/10.1186\/s13023-025-03547-0 (2025).","journal-title":"Orphanet J. Rar. Dis."},{"key":"35684_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.7326\/AITC202303210","volume":"176","author":"MW Bloom","year":"2023","unstructured":"Bloom, M. W. & Gorevic, P. D. Cardiac amyloidosis. Ann. Intern. Med. 176, 33\u201348. https:\/\/doi.org\/10.7326\/AITC202303210 (2023).","journal-title":"Ann. Intern. Med."},{"key":"35684_CR4","doi-asserted-by":"publisher","first-page":"16145","DOI":"10.3390\/ijms232416145","volume":"23","author":"M Nuvolone","year":"2022","unstructured":"Nuvolone, M., Girelli, M. & Merlini, G. Oral therapy for the treatment of transthyretin-related amyloid cardiomyopathy. Int. J. Mol. Sci. 23, 16145. https:\/\/doi.org\/10.3390\/ijms232416145 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"35684_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14779072.2025.2463333","volume":"23","author":"A Achten","year":"2025","unstructured":"Achten, A. et al. Is transthyretin amyloid cardiomyopathy heading towards losing its rare disease classification?. Expert Rev. Cardiovasc. Ther. 23, 1\u20134. https:\/\/doi.org\/10.1080\/14779072.2025.2463333 (2025).","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"35684_CR6","doi-asserted-by":"publisher","first-page":"176142","DOI":"10.1016\/j.ejphar.2023.176142","volume":"960","author":"V Golatkar","year":"2023","unstructured":"Golatkar, V. & Bhatt, L. K. Emerging therapeutic avenues in cardiac amyloidosis. Euro. J. Pharm. 960, 176142. https:\/\/doi.org\/10.1016\/j.ejphar.2023.176142 (2023).","journal-title":"Euro. J. Pharm."},{"key":"35684_CR7","doi-asserted-by":"publisher","first-page":"4857","DOI":"10.1016\/j.cell.2021.08.013","volume":"184","author":"MR Sawaya","year":"2021","unstructured":"Sawaya, M. R., Hughes, M. P., Rodriguez, J. A., Riek, R. & Eisenberg, D. S. The expanding amyloid family: Structure, stability, function, and pathogenesis. Cell 184, 4857\u20134873 (2021).","journal-title":"Cell"},{"key":"35684_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/01.JAA.0000697236.11386.3a","volume":"33","author":"T McVeigh","year":"2020","unstructured":"McVeigh, T. & Tennyson, C. Understanding and recognizing cardiac amyloidosis. Jaapa 33, 16\u201320 (2020).","journal-title":"Jaapa"},{"key":"35684_CR9","doi-asserted-by":"publisher","first-page":"52300","DOI":"10.7554\/eLife.52300","volume":"9","author":"P Kazman","year":"2020","unstructured":"Kazman, P. et al. Fatal amyloid formation in a patient\u2019s antibody light chain is caused by a single point mutation. elife 9, 52300 (2020).","journal-title":"elife"},{"key":"35684_CR10","doi-asserted-by":"publisher","first-page":"9992","DOI":"10.1073\/pnas.1300761110","volume":"110","author":"SC Penchala","year":"2013","unstructured":"Penchala, S. C. et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc. Natl. Acad. Sci. U. S. A. 110, 9992\u20139997. https:\/\/doi.org\/10.1073\/pnas.1300761110 (2013).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"35684_CR11","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.1182\/bloodadvances.2022007781","volume":"6","author":"E Muchtar","year":"2022","unstructured":"Muchtar, E. et al. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis. Blood Adv. 6, 5429\u20135435 (2022).","journal-title":"Blood Adv."},{"key":"35684_CR12","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00277-023-05090-z","volume":"102","author":"K Suzuki","year":"2023","unstructured":"Suzuki, K. et al. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: Subgroup analysis of ANDROMEDA. Ann. Hematol. 102, 863\u2013876. https:\/\/doi.org\/10.1007\/s00277-023-05090-z (2023).","journal-title":"Ann. Hematol."},{"key":"35684_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ejhf.2027","volume":"23","author":"T Damy","year":"2021","unstructured":"Damy, T. et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur. J. Heart Fail. 23, 277\u2013285. https:\/\/doi.org\/10.1002\/ejhf.2027 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"35684_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jccase.2021.01.007","volume":"23","author":"M Nakamura","year":"2021","unstructured":"Nakamura, M., Imamura, T. & Kinugawa, K. Patisiran for advanced heart failure with hereditary transthyretin cardiac amyloidosis. J. Cardiol. Cases 23, 177\u2013180. https:\/\/doi.org\/10.1016\/j.jccase.2021.01.007 (2021).","journal-title":"J. Cardiol. Cases"},{"key":"35684_CR15","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jaccao.2022.08.011","volume":"4","author":"MC Minnema","year":"2022","unstructured":"Minnema, M. C. et al. Outcomes by cardiac stage in patients with newly diagnosed AL amyloidosis: phase 3 ANDROMEDA trial. J. Cardiol. cases 4, 474\u2013487. https:\/\/doi.org\/10.1016\/j.jaccao.2022.08.011 (2022).","journal-title":"J. Cardiol. cases"},{"key":"35684_CR16","doi-asserted-by":"crossref","unstructured":"Lee, A. Acoramidis: First approval. Drugs, 1\u20135 (2025).","DOI":"10.1007\/s40265-025-02164-2"},{"key":"35684_CR17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/phar.4639","volume":"45","author":"EL Hellenbart","year":"2025","unstructured":"Hellenbart, E. L., Ipema, H. J., Rodriguez-Ziccardi, M. C., Krishna, H. & DiDomenico, R. J. Disease-modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications. Pharmacotherapy 45, 124\u2013144 (2025).","journal-title":"Pharmacotherapy"},{"key":"35684_CR18","doi-asserted-by":"publisher","first-page":"16145","DOI":"10.3390\/ijms232416145","volume":"23","author":"M Nuvolone","year":"2022","unstructured":"Nuvolone, M., Girelli, M. & Merlini, G. Oral therapy for the treatment of transthyretin-related amyloid cardiomyopathy. Int. J. Mol. Sci. 23, 16145. https:\/\/doi.org\/10.3390\/ijms232416145 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"35684_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/cpdd.700","volume":"9","author":"JC Fox","year":"2020","unstructured":"Fox, J. C. et al. First-in-human study of AG10, a novel, oral, specific, selective, and potent transthyretin stabilizer for the treatment of transthyretin amyloidosis: A phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic study in healthy adult volunteers. Clin. Pharmacol. Drug. Dev. 9, 115\u2013129. https:\/\/doi.org\/10.1002\/cpdd.700 (2020).","journal-title":"Clin. Pharmacol. Drug. Dev."},{"key":"35684_CR20","doi-asserted-by":"publisher","first-page":"131413","DOI":"10.1016\/j.matchemphys.2025.131413","volume":"346","author":"A Farooq","year":"2025","unstructured":"Farooq, A. et al. Unveiling the antistatic, anticancer and antibacterial properties of boron nitride and ionic liquid blended polyurethane elastomer films. Mater. Chem. Phys. 346, 131413. https:\/\/doi.org\/10.1016\/j.matchemphys.2025.131413 (2025).","journal-title":"Mater. Chem. Phys."},{"key":"35684_CR21","doi-asserted-by":"publisher","first-page":"116420","DOI":"10.1016\/j.molliq.2021.116420","volume":"337","author":"M Gano","year":"2021","unstructured":"Gano, M., Klebeko, J. & Pe\u0142ech, R. Efficient esterification of curcumin in bis (trifluoromethylsulfonyl) imide-based ionic liquids. J. Mol. Liq. 337, 116420. https:\/\/doi.org\/10.1016\/j.molliq.2021.116420 (2021).","journal-title":"J. Mol. Liq."},{"key":"35684_CR22","doi-asserted-by":"publisher","first-page":"338900","DOI":"10.1016\/j.aca.2021.338900","volume":"1181","author":"MN Emaus","year":"2021","unstructured":"Emaus, M. N. & Anderson, J. L. Magnetic ionic liquids as microRNA extraction solvents and additives for the exponential amplification reaction. Anal. Chim. Acta 1181, 338900. https:\/\/doi.org\/10.1016\/j.aca.2021.338900 (2021).","journal-title":"Anal. Chim. Acta"},{"key":"35684_CR23","doi-asserted-by":"publisher","first-page":"126002","DOI":"10.1016\/j.molliq.2024.126002","volume":"413","author":"S Sangeeta","year":"2024","unstructured":"Sangeeta, S., Sarkar, A. & Tomar, R. Unveiling the potential: 1,3-benzodioxole-based ionic liquids as dynamic players against cancer. J. Mol. Liq. 413, 126002. https:\/\/doi.org\/10.1016\/j.molliq.2024.126002 (2024).","journal-title":"J. Mol. Liq."},{"key":"35684_CR24","doi-asserted-by":"publisher","first-page":"124284","DOI":"10.1016\/j.molliq.2024.124284","volume":"398","author":"S Sangeeta","year":"2024","unstructured":"Sangeeta, S. et al. Biophysical insight into the binding mechanism of 1,3-benzodioxole-based lidocaine tagged ionic liquids with BSA: An in-silico, and spectroscopic studies. J. Mol. Liq. 398, 124284. https:\/\/doi.org\/10.1016\/j.molliq.2024.124284 (2024).","journal-title":"J. Mol. Liq."},{"key":"35684_CR25","doi-asserted-by":"publisher","first-page":"121803","DOI":"10.1016\/j.saa.2022.121803","volume":"285","author":"MA Siddiquee","year":"2023","unstructured":"Siddiquee, M. A. et al. Spectroscopic and DFT study of imidazolium based ionic liquids with broad spectrum antibacterial drug levofloxacin. Spect. Chimica. Acta. Part A 285, 121803. https:\/\/doi.org\/10.1016\/j.saa.2022.121803 (2023).","journal-title":"Spect. Chimica. Acta. Part A"},{"key":"35684_CR26","doi-asserted-by":"publisher","first-page":"123325","DOI":"10.1016\/j.molliq.2023.123325","volume":"391","author":"S Sangeeta","year":"2023","unstructured":"Sangeeta, S. et al. Synthesis of 1, 3-benzodioxole-based procaine-tagged ionic liquids and investigation of its physiochemical and anti-cancer properties against A549 cells. J. Mol. Liq. 391, 123325. https:\/\/doi.org\/10.1016\/j.molliq.2023.123325 (2023).","journal-title":"J. Mol. Liq."},{"issue":"1","key":"35684_CR27","doi-asserted-by":"publisher","first-page":"28980","DOI":"10.1038\/s41598-024-74250-6","volume":"14","author":"S Kalhor","year":"2024","unstructured":"Kalhor, S. & Fattahi, A. Combinatorial MD\/QM studies to develop novel ionic liquid-based anticancer drug delivery systems with aminium derived from carbohydrates as cationic components. Sci. Rep. 14(1), 28980. https:\/\/doi.org\/10.1038\/s41598-024-74250-6 (2024).","journal-title":"Sci. Rep."},{"key":"35684_CR28","doi-asserted-by":"publisher","first-page":"119277","DOI":"10.1016\/j.molliq.2022.119277","volume":"359","author":"J Saraswat","year":"2022","unstructured":"Saraswat, J., Riaz, U. & Patel, R. In-silico study for the screening and preparation of ionic liquid-AVDs conjugate to combat COVID-19 surge. J. Mol. Liq. 359, 119277. https:\/\/doi.org\/10.1016\/j.molliq.2022.119277 (2022).","journal-title":"J. Mol. Liq."},{"key":"35684_CR29","doi-asserted-by":"publisher","first-page":"115159","DOI":"10.1016\/j.molliq.2020.115159","volume":"325","author":"A Kumar","year":"2021","unstructured":"Kumar, A., Kumari, K., Singh, S., Bahadur, I. & Singh, P. Noscapine anticancer drug designed with ionic liquids to enhance solubility: DFT and ADME approach. J. Mol. Liq. 325, 115159. https:\/\/doi.org\/10.1016\/j.molliq.2020.115159 (2021).","journal-title":"J. Mol. Liq."},{"key":"35684_CR30","doi-asserted-by":"publisher","first-page":"112447","DOI":"10.1016\/j.jphotobiol.2022.112447","volume":"231","author":"NM Mahani","year":"2022","unstructured":"Mahani, N. M., Mostaghni, F. & Shafiekhani, H. Cuspareine as alkaloid against COVID-19 designed with ionic liquids: DFT and docking molecular approaches. J. Photochem. Photobiol. B 231, 112447. https:\/\/doi.org\/10.1016\/j.jphotobiol.2022.112447 (2022).","journal-title":"J. Photochem. Photobiol. B"},{"key":"35684_CR31","unstructured":"Frisch, M. J. et al. Gaussian 09, Revision A.02, Gaussian, Inc., Wallingford CT (2013)."},{"key":"35684_CR32","doi-asserted-by":"publisher","first-page":"5648","DOI":"10.1063\/1.464913","volume":"98","author":"AD Becke","year":"1993","unstructured":"Becke, A. D. Density-functional thermochemistry. III. The role of exact exchange. Chem. Phys. 98, 5648\u20135652. https:\/\/doi.org\/10.1063\/1.464913 (1993).","journal-title":"Chem. Phys."},{"key":"35684_CR33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s10822-025-00593-5","volume":"39","author":"N Madadi Mahani","year":"2025","unstructured":"Madadi Mahani, N., Hamidian, H., Fozooni, S. & Salajeghe, M. Synthesis, TD-DFT calculations, molecular docking and ADME studies of new spiro-oxindole derivatives containing 5 (4H)-oxazolone as anti-viral and anti-bacterial agents. J. Comput. Aided. Mol. Des. 39, 14. https:\/\/doi.org\/10.1007\/s10822-025-00593-5 (2025).","journal-title":"J. Comput. Aided. Mol. Des."},{"key":"35684_CR34","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/jcc.22885","volume":"33","author":"T Lu","year":"2012","unstructured":"Lu, T. & Chen, F. Multiwfn: A multifunctional wavefunction analyzer. J. Comput. Chem. 33, 580\u2013592. https:\/\/doi.org\/10.1002\/jcc.22885 (2012).","journal-title":"J. Comput. Chem."},{"key":"35684_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey, W., Dalke, A. & Schulten, K. V. M. D. Visual molecular dynamics. J. Mol. Graph. 14, 33\u201338. https:\/\/doi.org\/10.1016\/0263-7855(96)00018-5 (1996).","journal-title":"J. Mol. Graph."},{"key":"35684_CR36","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.1021\/acs.jpca.4c01667","volume":"128","author":"C Guerra","year":"2024","unstructured":"Guerra, C., Burgos, J., Ayarde-Henr\u00edquez, L. & Chamorro, E. Formulating reduced density gradient approaches for noncovalent interactions. J. Phys. Chem. A 128, 6158\u20136166. https:\/\/doi.org\/10.1021\/acs.jpca.4c01667 (2024).","journal-title":"J. Phys. Chem. A"},{"key":"35684_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455\u2013461. https:\/\/doi.org\/10.1002\/jcc.21334 (2010).","journal-title":"J. Comput. Chem."},{"key":"35684_CR38","doi-asserted-by":"publisher","unstructured":"Bank. R. P. D. RCSB PDB-5m8p: Crystal structure of human tyrosinase related protein 1 in complex with tyrosine. https:\/\/doi.org\/10.2210\/pdb5M8P\/pdb (2017)","DOI":"10.2210\/pdb5M8P\/pdb"},{"key":"35684_CR39","doi-asserted-by":"publisher","unstructured":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7, 42717. https:\/\/doi.org\/10.1038\/srep42717 (2017).","DOI":"10.1038\/srep42717"},{"key":"35684_CR40","doi-asserted-by":"crossref","unstructured":"ADMETlab 2.0: An integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 49(W1), W5\u2013W14 (2021).","DOI":"10.1093\/nar\/gkab255"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35684-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35684-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35684-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:06:09Z","timestamp":1771434369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35684-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["35684"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-35684-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"2 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6540"}}